Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Bevacizumab (Primary) ; Vorinostat (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 29 May 2015 Primary endpoint has not been met (6-month progression-free survival) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.